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RESEARCH ARTICLE
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Due to the high burden of dengue disease worldwide, a better understanding of the interac-
tions between dengue virus (DENV) and its human host cells is of the utmost importance.
Although microRNAs modulate the outcome of several viral infections, their contribution to
DENV replication is poorly understood.
Methods and principal findings
We investigated the microRNA expression profile of primary human macrophages chal-
lenged with DENV and deciphered the contribution of microRNAs to infection. To this end,
human primary macrophages were challenged with GFP-expressing DENV and sorted to
differentiate between truly infected cells (DENV-positive) and DENV-exposed but non-
infected cells (DENV-negative cells). The miRNAome was determined by small RNA-Seq
analysis and the effect of differentially expressed microRNAs on DENV yield was examined.
Five microRNAs were differentially expressed in human macrophages challenged with
DENV. Of these, miR-3614-5p was found upregulated in DENV-negative cells and its over-
expression reduced DENV infectivity. The cellular targets of miR-3614-5p were identified by
liquid chromatography/mass spectrometry and western blot. Adenosine deaminase acting
on RNA 1 (ADAR1) was identified as one of the targets of miR-3614-5p and was shown to
promote DENV infectivity at early time points post-infection.
Conclusion/Significance
Overall, miRNAs appear to play a limited role in DENV replication in primary human macro-
phages. The miRNAs that were found upregulated in DENV-infected cells did not control the
production of infectious virus particles. On the other hand, miR-3614-5p, which was
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upregulated in DENV-negative macrophages, reduced DENV infectivity and regulated
ADAR1 expression, a protein that facilitates viral replication.
Author summary
Dengue is the most common mosquito-borne disease worldwide and it is an increasing
global concern for public health as its etiological agent, dengue virus (DENV), keeps
spreading around the globe. Currently there are no specific antiviral therapies available to
treat the disease. Macrophages are important target cells during natural DENV infection
of humans. Here, we unraveled the importance of miRNAs in DENV replication in
human primary macrophages. The expression profile of miRNAs was determined in truly
DENV-infected cells and cells that were exposed but not productively infected by the
virus by RNA sequencing. We revealed that only five miRNAs are regulated in primary
macrophages challenged with DENV. These results show that miRNAs do not play a
major role in DENV replication. Unexpectedly, we did identify a miRNA with moderate
yet significant antiviral properties to DENV. Moreover, miRNA-3614-5p was found to
not only decrease DENV but also West Nile virus infectivity. Mass spectrometry and bio-
informatics analysis identified adenosine deaminase acting on RNA 1 (ADAR1) as one of
the targets. Moreover, ADAR1 was observed to promote the early stages of DENV replica-
tion. Collectively, our study broadens the knowledge of the contribution of human miR-
NAs in shaping the network of interactions between DENV and its human host cells.
Introduction
Dengue, the arboviral disease with the highest incidence worldwide, is caused by dengue virus
(DENV). There are four antigenically distinct serotypes of DENV (DENV-1 to -4) which co-
circulate in endemic areas [1]. Annually, an estimated 390 million individuals are infected of
which 96 million develop a clinically apparent disease [2]. Disease manifestations range from a
mild self-limiting febrile illness to life-threatening severe dengue characterized by plasma leak-
age, hemorrhages and organ impairment [3]. The majority of individuals with severe disease
have a heterologous secondary DENV infection [4]. Although DENV vaccination reduces the
incidence of severe disease, there are concerns regarding the overall efficacy and safety of the
first licensed DENV vaccine [5]. Furthermore, there are no specific antiviral therapies available
to treat the disease.
DENV belongs to the family Flaviviridae, which encompasses re-emerging arboviruses such
as Zika and West Nile viruses (WNV). In humans, DENV replicates predominantly in den-
dritic cells, monocytes, macrophages and hepatocytes [6]. Upon infection of cells, the 10.7 Kb
positive-sense, single stranded RNA genome is translated into a single polyprotein. Thereafter,
the polyprotein is cleaved into three structural proteins (capsid, prM and E) and seven non-struc-
tural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) by viral and cellular proteases [7].
The non-structural viral proteins will, subsequently, in companion with several cellular proteins,
start negative strand RNA synthesis. The negative RNA strand serves as a template for the synthe-
sis of new positive RNA strands, which then initiate a new translation cycle or associate with cap-
sid proteins to form a nucleocapsid [8]. Virus assembly starts by budding of a newly formed
nucleocapsid into the endoplasmic reticulum lumen, thereby acquiring a lipid membrane with
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prM and E. Progeny virions mature on the trans-Golgi compartment and exit from the cell by
exocytosis [8].
Many cellular proteins have been described to aid in DENV replication [9–12]. For exam-
ple, adenosine deaminase acting on RNA 1 (ADAR1) has been identified as a proviral factor
for DENV replication [13,14]. ADAR1 catalyzes the hydrolytic deamination of adenosine to
produce inosine in dsRNA substrates, a process known as A-to-I RNA editing. ADAR
enzymes can, however, also influence viral replication in an edit-independent manner [15,16].
The mechanism by which ADAR1 promotes DENV replication remains to be elucidated.
How microRNAs (miRNAs) participate in DENV replication is, however, poorly under-
stood. miRNAs are a class of small non-coding RNAs regulating post-transcriptional expres-
sion of genes. miRNAs target mRNAs in a sequence-specific manner leading to mRNA
degradation or translational repression [17]. It has been estimated that more than 60% of all
mammalian mRNAs are targeted by miRNAs [18] and as a consequence, miRNAs contribute
to many cellular processes like cell survival, proliferation and differentiation [19]. In addition,
miRNAs are part of the intricate network of interactions between pathogens and host cells
[20,21]. Indeed, DENV-challenged cell lines were recently shown to have an altered miR-
NAome compared to non-infected cells [22–25]. For example, increased expression of miR-
30e was observed in DENV-infected U937 and Hela cells. MiR-30e was found to act as a
restriction factor by promoting interferon (IFN)-β production through the NF-κB pathway
[23]. On the other hand, miR-146a is upregulated in DENV-infected human monocytes and
miR-146a overexpression resulted in increased DENV replication by damping IFN production
[24]. Furthermore, we observed downregulation of miR-133a in DENV-infected Vero cells
[25]. This was associated with increased expression of polypirimidine tract binding protein, a
protein involved in DENV genome replication [25].
In the present study, we evaluated the miRNAome of DENV-challenged human primary
monocyte-derived macrophages (MDMs). Furthermore, we differentiated between DENV-
positive and DENV-negative cells in the challenged cell population. MDMs were chosen as
macrophages represent important target cells for virus replication during natural infection in
humans [26]. Five miRNAs were differentially expressed between DENV-positive and DENV-
negative cells. Of these, miR-3614-5p is upregulated in DENV-negative cells and its overex-
pression reduced DENV infectivity. Subsequent proteomic and biochemical analysis revealed
ADAR1 as one of the targets of miR-3614-5p. Taken together, DENV replication is influenced
by miR-3614-5p, a miRNA that targets the DENV proviral protein ADAR1.
Methods
Cell culture
Baby hamster kidney cells clone 21 (BHK-21; ATCC: CCL-110) were cultured in RPMI-1640
supplemented with 10% fetal bovine serum (FBS) (Lonza, Basel, Switzerland), 100U/ml peni-
cillin and 100mg/ml streptomycin (PAA Laboratories, Pasching, Austria). BHK-21 clone
15 cells are not commercially available and were a kind gift from Richard Kuhn (Purdue Uni-
versity). They were grown in Dulbecco’s minimal essential medium (DMEM) (Gibco, the
Netherlands) supplemented with 10% FBS, 100U/mL penicillin and 100mg/mL streptomycin,
100 μM of non-essential aminoacids (Gibco) and 10mM of hepes (Gibco). Huh7 cells (JCRB
0403) were a kind gift from Tonya Colpitts (University of South Carolina) and were cultured
in DMEM/Glutamax supplemented with 10% FBS, 100U/mL penicillin and 100mg/mL strep-
tomycin. Wild-type (WT) mouse embryonic fibroblasts (MEFs), p53 knockout (KO) MEFs
(p53-/-) and p53/ADAR1 KO MEFs (p53-/-ADAR1-/-) were a kind gift from Mary A. O’Connell
(CEITEC Masaryk University) and were cultured in DMEM supplemented with 10% FBS,
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100U/mL penicillin, 100mg/mL streptomycin, 2mM of L-glutamine, 0.1mM of 2-mercap-
toethanol (Gibco) and 20mM hepes. C6/36 Aedes albopictus cells (ATCC: CRL-1660) were
maintained in minimal essential medium (Invitrogen, Carlsbad, California, USA) supple-
mented with 10% FBS, 25 mM HEPES, 7.5% sodium bicarbonate, 100U/mL penicillin and
100mg/mL streptomycin, 200 mM glutamine, and 100 μM nonessential amino acids. All mam-
malian cells were cultured at 37˚C and 5% CO2 and C6/36 cells were cultured at 28˚C and 5%
CO2.
Generation and characterization of virus stocks
DENV-2 strain 16681 was propagated on C6/36 cells, as described previously [27]. Recombi-
nant GFP-DENV was generated from the infectious clone pFK-DV-G2A strain 16681 (kind
gift from Ralf Bartenschlager University of Heidelberg, [28]). The pFK-DV-G2A clone was
propagated in E. coli strain D5α. Upon plasmid purification, the plasmid was linearized with
XbaI (New England Biolabs, Ipswich, Massachusetts, USA) and capped RNA transcripts were
synthesized by use of an SP6 polymerase (New England Biolabs). Viruses were harvested at 72
hours post-transfection (hpt) of RNA in BHK-21 cells via electroporation (Biorad Gene Pulser
Xcell machine; 850 V, 25 μF, no resistance). Thereafter, GFP-DENV was propagated once by
infecting C6/36 cells (MOI 0.1). Progeny virions were harvested, aliquoted and snap-frozen at
120 hours post-infection (hpi). WNV strain NY385-99 was a generous gift from Jaap Gouds-
mit (Crucell Holland BV) and was propagated on BHK-21 cells, as previously described [29].
All virus preparations were characterized, as described before [27,30] by determination of the
number of infectious particles by plaque assay on BHK-15 cells and the number of genome-
equivalent particles by Q-RT-PCR. UV-inactivated GFP-DENV was obtained by exposure of
the virus to UV-light for 4h. Inactivation was confirmed by plaque assay.
Human macrophage differentiation
Macrophages were obtained by differentiation of human monocytes isolated from peripheral
blood mononuclear cells (PBMCs), as described by us before [31]. Briefly, PBMCs were iso-
lated from buffy coats by Ficoll-Paque (GE Healthcare, Hoevelaken, The Netherlands) and
monocytes were obtained by adherence to cell culture plates. Monocytes were differentiated to
macrophages in presence of recombinant human M-CSF (ProSpec-Tany TechnoGene Ltd,
Rehovot, Israel). Monocyte-derived macrophages (MDMs) were characterized by their mor-
phology and the expression pattern CD14+, CD80low, CD86+, CD206low and MHC-II+.
DENV infections
MDMs were mock-infected, challenged with UV-inactivated GFP-DENV (UVi-DENV) or
with GFP-DENV. A viral dose of 92 genome equivalents per cell (MOI 10) was used. Infection
was allowed for 2 h, after which cells were washed 3 times and fresh RPMI-1640 medium sup-
plemented with 20% FBS and 10ng/ml of M-CSF was added. Cells and supernatants were har-
vested at the indicated time points. Huh7 and MEF cells were infected at MOIs of 1, 5 and 10
and cells and supernatants were collected at the specified time points.
Small RNA sequencing
Total RNA was extracted from cells using the mirVana isolation kit (Ambion, life technologies,
USA) following the manufacturer’s instructions. cDNA libraries were prepared from 2 μg
RNA using the Illumina TruSeq Small RNA sample preparation kit and small RNA indices
(Illumina, San Diego, California, USA). Samples belonging to the same donor were pooled
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and sequencing was performed on a HiSeq 2000 (Illumina) following manufacturer’s instruc-
tions with paired 50 base reads plus a 6-base index read. Raw reads were trimmed and de-bar-
coded by CLC Genomics Workbench (CLC bio, Cambridge, Massachusetts, USA). The
miRanalizer platform [32] was used to map reads to known human miRNAs (based on miR-
Base V.18). Read counts were standardized to reads per million and imported into GeneSpring
GX 12.5 PA (Agilent Technologies, Santa Clara, California, USA). Statistical significance
(p<0.05) was examined by an ANOVA test and correction for multiple comparisons was per-
formed according to the Benjamini and Hochberg method. Expression profiles were visualized
in heat maps using unsupervised clustering analysis with a Pearson correlation using Genesis.
Transfection of mimics and siRNAs
Huh7 and MEFs cells were seeded in 24-well plates at a cell density of 7.0x104 and 2.0 x104
cells per well, respectively. At 24 h post-seeding, cells were transfected with 1.5μl of lipofecta-
mine RNAi/Max (Invitrogen) and a final concentration of 10mM of miRNAs mimics
(Ambion, cat 4464066; miR-3960 (ID: MC22178), miR-4508 (ID: MC21571), miR-4301 (ID:
MC17762), miR-181a (ID: MC10381) and miR-3614-5p (ID: MC20080)). A mimic negative
control (Ambion, Cat 4464058) was also used. Cells were infected at 24 hpt. The transfection
efficiency was assessed by real time PCR. cDNA synthesis and PCRs were performed with the
miRCURY LNA universal RT miRNA PCR system (Exiqon, Vedbaek, Denmark) following
the manufacturer’s instructions. Primers targeting the mature sequence of the mentioned miR-
NAs were obtained from Exiqon (LNA PCR primers set). The comparative Ct method was
used taking into account the efficiency of the PCR and with miR-16-5p as a reference miRNA.
The PCR efficiency was calculated by LinRegPCR (Academic Medical Center, Amsterdam, the
Netherlands).
Cell viability assays
To determine cell viability of transfected and/or infected cells, cells were trypsinized and
stained with the ViViD dye (Life technologies), following manufacturer’s instructions.
Flow cytometry and sorting
At 24 hpi, MDMs were collected and sorted in a Moflo XDP (Beckman coulter) on the basis of
GPF expression. Both fractions, GFP-positive and GFP-negative were collected. Also, mock-
infected cells were passed through the cytometer and the whole cell population was recovered.
The number of infected cells was determined by flow cytometry on the basis of GFP- or E-pro-
tein expression. For E staining, cells were permeabilized with 0.5% saponin and stained using
the 4G2 antibody (Merk Millipore, Billerica, Massachusetts, USA) and a rabbit anti-mouse
IgG coupled to AF647 (Molecular probes, Eugene, Oregon, USA). Flow cytometry was carried
out in a LSRII cytometer (BD Biosciences) and analysis was performed with Kaluza 1.1.
Liquid chromatography and mass spectrometry (LC/MS)
Huh7 cells were transfected with a mimic negative control or with miR3614-5p mimics. At 24
hpt, proteins were extracted with RIPA lysis buffer system (Santa Cruz, Dallas, TX, USA). Pro-
teins were fractionated by SDS-PAGE at 60V for 6 minutes for a total migration length of ~0.5
cm. Gels were rinsed in deionized water and stained overnight with Coomassie G250 (Biorad).
Proteins in the entire 0.5 cm gel section underwent standard in-gel tryptic digestion including
reduction and alkylation. Peptides were extracted from each gel section and fractionated by a
nanoflow reversed-phase ultra-high pressure liquid chromatography system (nanoLC, Dionex)
microRNA-3614-5p reduces DENV and ADAR1 expression
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005981 October 18, 2017 5 / 24
in-line with a Q-Exactive plus mass spectrometer (Thermo Scientific). Peptides were back-
flush eluted onto a 50 cm × 75 μm i.d. nanocolumn (Dionex). Samples were analyzed with a
1.5-hr linear gradient (3–50% acetonitrile with 0.1% formic acid), and data were acquired in a
data-dependent manner using a top 12 method with a dynamic exclusion of 20 seconds. For
data processing, PEAKS 7.5 software (Bioinformatics Solutions Inc., Waterloo, Ontario, Can-
ada) was applied to the spectra generated by the Q-exactive plus mass spectrometer to search
against a Human Protein database (trEmble/SwissProt entries) (Uniprot). The false discovery
rate was set at 0.1%. Label free quantitation based on the expectation-maximization algorithm
was performed in the Q module of PEAKs 7.5. Peptide features and proteins (detected in all 4
samples) were considered significantly different between groups at a fold change1.5 and p
value 0.05.
Pathway and gene ontology enrichment analysis
To further understand the biological relevance of differentially expressed proteins, we per-
formed functional enrichment analysis in the context of the Gene Ontology (GO), Kyoto
Encyclopedia of Genes and Genomes (KEGG) and Reactome databases using the ClueGO
Cytoscape plugin. A p-value cut-off of 0.001 was used to identify enriched processes. A kappa
score was calculated to reflect the relationships between the terms based on the similarity of
their associated genes, with the threshold set at 0.3.
Western blot
Proteins were extracted from cells using the RIPA Lysis Buffer System (Santa Cruz Biotechnol-
ogy) and the protein concentration was determined via the Bradford assay (Expedeon, Swave-
sey, UK). Samples (50–90 μg protein) were mixed with 5x Laemmli buffer and heated at 95˚C
for 5 min for denaturation. Proteins were fractionated by SDS-PAGE and transferred to Poly-
vinylidene difluoride membranes (Immobilon-P, Millipore, Darmstad, Germany). Blocking
was performed with 5% bovine serum albumin (GE Healthcare) for 10 min. Primary antibod-
ies were added overnight at 4˚C. The antibody against ADAR1 (Santa Cruz Biotechnology)
was diluted 1:1000 and the GAPDH antibody (Abcam, Cambridge, UK) was diluted 1:10000.
After extensive washing, membranes were incubated with secondary HRP-conjugated anti-
bodies, anti-mouse or anti-rabbit (Thermo Fisher Scientific), diluted 1:4000. Membranes were
extensively washed before detection. Pierce ECL western blotting substrate (Thermo Fisher
Scientific) or Super Signal West FEMTO (Thermo Fisher Scientific) was used for detection by
means of chemiluminescence using LAS-4000 mini camera system (Fujifilm Life Science Sys-
tems, Japan).
Statistical analysis
All data was analyzed in GraphPad Prism software and is presented as mean ± SEM. The tests
used to evaluate statistical differences between treatments are specified in each figure and a p
value0.05 was considered significant with p0.05 and p0.01.
Ethics statement
Buffy coats were obtained from adult healthy volunteers with written informed consent from
Sanquin blood bank (Groningen, the Netherlands), in line with the declaration of Helsinki. All
samples were analyzed anonymously.
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Results
DENV alters the expression profile of miRNAs in MDMs
Our initial objective was to provide an insight into the miRNAome of primary human MDMs
challenged with DENV. Previously, we and others reported that MDMs are permissive to
DENV [31,33,34]. However, even upon DENV challenge at high MOI doses, only a fraction of
the cells is productively infected [31,33]. Therefore, we here decided to differentiate between
infected cells (DENV-plus) and cells that, despite being in contact with the virus, were not
infected (DENV-neg). To facilitate this, GFP-encoding recombinant DENV (GFP-DENV) was
used in our experiments [28].
Human primary MDMs from three different blood donors, which were cultured indepen-
dently, were challenged with GFP-DENV at MOI 10 (92 genome equivalents per cell). At these
conditions, we anticipate that most of the cells have been in contact with the virus. At 24 hpi,
the percentage of infection was determined by means of GFP expression and infectious virus
particle production was measured by plaque assay. The percentage of infection was 30.3, 36.6,
and 48.4, with corresponding titers of 2.43x105, 1.09x105 and 1.12x106 PFU/ml, respectively
(S1 Fig). For small RNA sequencing, DENV-challenged MDMs were sorted in DENV-plus
and DENV-neg cell populations and as controls DENV-challenged MDMs without sorting
(DENV-challenge), UVi-GFP-DENV (UVi-DENV) and two sets of mock-infected MDMs
were added (Fig 1A). One set of mock-infected MDMs were passed through the FACS sorter
and compared with non-sorted mock-infected cells to assess the effect of the sorting procedure
on miRNA expression. On average, 700 miRNAs were identified per condition, but only those
with an average of at least 100 reads per million (in total 219) were taken into account for fur-
ther analysis. The expression profile of the identified miRNAs is shown in S2 Fig. Notably,
most miRNAs cluster on the basis of the donor rather than the condition, highlighting the
intrinsic differences that exist among human donors and the limited changes induced by
DENV infection.
In order to detect miRNAs differentially expressed, we first compared the two sets of mocks
and found no differences between mock-infected cells with and without FACS sorting, dem-
onstrating that the sorting procedure did not affect miRNA expression (S3 Fig). For this rea-
son, we included the two sets of mocks in the following analysis. Only 20 miRNAs were
differentially expressed between all treatments (mock non- sorted, UVi-DENV, DENV-chal-
lenge, mock sorted, DENV-plus and DENV-neg (Fig 1B, ANOVA, p<0.05)). Upon multiple
testing correction using the Benjamini and Hochberg method, 5 of the miRNAs remained sig-
nificant (Fig 1C). The Tukey post hoc test revealed that in comparison to the mock-infected
cells, miR-4508, miR-3960, miR-3614-5p, miR-181a-3p are upregulated in DENV-challenged
cells; miR-4508, miR-3960, and miR-4301 are upregulated in the sorted DENV-plus cell popu-
lation; and miR-4508, miR-3960, miR-3614-5p and miR-181a-3p are upregulated in the
DENV-neg population. Furthermore, miR-3614-5p and miR-181a-3p were significantly upre-
gulated in the DENV-neg cell population when compared to the DENV-plus population. No
differences were found between UVi-DENV cells and mock-infected cells (Table 1), indicating
that viral replication is required for changes in the miRNAome. To validate the sequencing
results, we next analyzed the expression level of the miRNAs with the highest changes (miR-
4508 and miR-3960) by real-time PCR. This was assessed in a new set of three donors follow-
ing the same infection scheme. The results show a 6.9- and 6.1-fold change in miR-4508 and
miR-3960 expression levels in DENV-plus cells over mock-infected cells (Fig 2A). In DENV-
neg cells, a 1.8 fold change was seen for miR-4508 and no change in miR-3960 was observed
when related to mock-infected cells (Fig 2A). The correlation between the two data sets
microRNA-3614-5p reduces DENV and ADAR1 expression
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Fig 1. Differentially expressed miRNAs in MDMs challenged with DENV. (A) MDMs obtained from three
different blood donors (D28, D29 and D30) were treated as follows: 1) mock-infected and non-sorted, 2)
treated with UVi-DENV, 3) challenged with GFP-DENV (DENV-challenge), 4) mock-infected and passed
through the FACS sorter, 5) challenged with GFP-DENV and sorted for GFP positive cells (DENV-plus), 6)
challenged with GFP-DENV and sorted for GFP negative cells (DENV-neg). (B) Hierarchical unsupervised
microRNA-3614-5p reduces DENV and ADAR1 expression
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(sequencing and PCR) is statistically significant (Spearman correlation, p< 0.05, Fig 2B)
thereby validating the small-RNA seq-based expression profile.
miR-3614-5p overexpression reduces DENV replication
Small RNA-Seq analysis revealed that only a limited number of miRNAs are regulated in
DENV challenged MDMs. To evaluate whether the identified miRNAs influence DENV infec-
tivity, progeny DENV production was determined in MDMs prior transfected with miR-3960,
miR-4508, miR-4301, miR-181a, miR-3614-5p, or a negative control (NC) mimic. Although
the transfection of the miRNA mimics into MDMs was feasible, the transfection of the NC
mimic had a large negative impact on the percentage of infection (S4A Fig). These results
forced us to test other cell lines and eventually we found that transfection of Huh7 hepatic
human cells with NC mimics had no effect on DENV infectivity and cell viability (S4B and
S4C Fig). Furthermore, hepatocytes represent natural target cells for DENV replication
[26,35]. Unexpectedly, neither the percentage of infection nor the viral titers were affected by
miR-3960, miR-4508, miR-4301 and miR-181a in Huh7 cells following infection at MOIs 1, 5,
and 10 (Fig 3). On the contrary, viral titers were significantly reduced (on average 2.8 fold) at
all MOIs tested in Huh7 cells overexpressing miR-3614-5p (Fig 4A). In line with these results,
a subtle decrease in the number of released genome equivalent viral copies (Fig 4B) was
observed. The inhibitory effect of the miRNA on infectious virus particle production is still
detectable at 36 h but wanes thereafter (Fig 4C). We next investigated whether miR-3614-5p is
expressed in Huh7 cells with and without DENV challenge at MOIs 0.1 and 1 at 12, 24 and 48
hpi. The expression level of miR-3614-5p was found below the detection limit in all experi-
mental conditions tested. The absence or low expression level of miR-3614-5p in Huh7 cells
actually make these cells a more astringent model to assess the contribution of miR-3614-5p
during DENV infection. To investigate whether the observed effect of miR-3614-5p can be
extrapolated to other flaviviruses, we next evaluated the influence of miR-3614-5p on WNV
infectivity. WNV infection of miRNA-transfected Huh7 cells was performed at MOIs 0.5 and
1 and viral titers were determined at 12 hpi as WNV is highly infectious in Huh7 cells and rep-
licates faster than DENV. Overexpression of miR-3614-5p in Huh7 cells reduces WNV infec-
tivity to a similar extent as DENV (Fig 4D), indicating that miR-3614-5p has an antiviral effect
on both flaviviruses.
Pearson correlation of miRNAs showing differentially expressed miRNAs across the samples (ANOVA,
p<0.05). (C) Differentially expressed miRNAs across the samples after the Benjamini and Hochberg
correction for multiple testing (p<0.05).
https://doi.org/10.1371/journal.pntd.0005981.g001
Table 1. Fold changes of each miRNA between the indicated comparisons.
miRNA UVi-DENV vs Mock DENV-challenge vs Mock DENV-plus vs Mock DENV-neg vs Mock DENV-plus vs DENV-neg
hsa-miR-4508 2.73 28.85 103.43 9.04 11.44
hsa-miR-3960 1.55 14.41 44.07 4.2 10.49
hsa-miR-4301 1.41 1.95 4.05 -1.05 4.24
hsa-miR-3614-5p 1.03 3.07 2.35 9.18 -3.91
hsa-miR-181a-3p -1.29 1.53 1.33 1.96 -1.47
Red and blue colors indicate statistical significant differences in the indicated comparison as determined by the Tukey post hoc test. Red: upregulated
miRNAs, blue: downregulated miRNAs.
https://doi.org/10.1371/journal.pntd.0005981.t001
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Proteomic changes induced by miR-3614-5p
Based on the above observations, it is likely that miR-3614-5p negatively influences the expres-
sion of proteins and/or pathways that promote DENV/WNV replication in Huh7 cells. In
order to test this possibility, we first searched for in silico predicted targets of miR-3614-5p
using the bioinformatics tool miRWalk (which allows a simultaneous search in miRanda,
RNA22 and TargetScan) [36]. The identified targets are listed in S1 Table. In total, 694 poten-
tial targets were predicted by the four databases. We decided to further identify targets of miR-
3614-5p by mass spectrometry, for two reasons; first, computational algorithms have been
described to miss real targets and predict large numbers of false positives [37,38] and second,
they do not address the context dependency of miRNA/mRNA interactions. In total 2,842 pro-
teins were identified by label free LC/MS (S2 Table). Of these, 29 proteins were significantly
differentially expressed with a minimum fold change of 1.5 between NC and miR-3614-5p-
overexpressing cells (Fig 5A). Notably, 9 proteins were downregulated and 20 proteins were
upregulated in cells overexpressing miR-3614-5p. Furthermore, of these 9 proteins, only
ADAR1 and isoform 3 of nucleoside diphosphate B (NME2) were predicted by bioinformatics
tools (underlined/bold in Fig 5A), ratifying the aforementioned difficulties of computational
methods. ADAR1 was predicted by all four algorithms (miRWalk, miRanda, RNA22 and Tar-
getScan) and NME2 was predicted only by RNA22.
Due to the action of miRNAs, it is likely that the 9 downregulated proteins are direct targets
of miRNA-3614-5p. In contrast, the upregulation of the remaining proteins is likely the result
of an indirect effect of miR-3614-5p. A gene-set enrichment analysis with particular attention
to GO biological processes and KEGG pathways was performed to better understand the
involvement of the 29 deregulated proteins in DENV infectivity. As shown in Fig 5B and 5C
and S3 Table, the majority of the differentially expressed proteins are associated with the
immune response and the organization of the cytoskeleton, two pathways that viruses hijack
in order to promote infection. In addition, four proteins were associated with viral response:
Fig 2. Validation of the miRNA expression profile. (A) miR-3960 and miR-4508 expression was determined by real-time PCR using specific
primers for the mature form of the miRNAs. Fold changes of the respective comparisons were determined through the comparative Ct method
taking into account the PCR efficiency and miRNA-16-5p as reference miRNA. Data is presented as mean ± SEM from three different blood
donors. (B) Spearman correlation between the fold changes obtained by RNA sequencing and real-time PCR.
https://doi.org/10.1371/journal.pntd.0005981.g002
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ADAR1, peptidyl prolyl cis-trans isomerase A (PPIA), serpin B3 (SERPINB3) and isoform 4 of
poly(rC)-binding protein 1 (PCBP2).
miR-3614-5p mediates ADAR1 downregulation
Our results revealed that multiple proteins are potentially regulated by miR-3614-5p. We con-
sidered ADAR1 as an interesting candidate for further validation as ADAR1 is 1) predicted in
silico as a target by the four programs used, 2) downregulated upon overexpression of miR-
3614-5p in our proteomic analysis, and 3) described as a proviral factor for several viruses
including DENV [13,14]. There are two isoforms of ADAR1: the constitutively expressed
ADAR1 p110 and the interferon (IFN)-induced p150. The p110-isoform accumulates in the
nucleus and edits dsRNA before nuclear export. The p150 isoform is active in both the nucleus
Fig 3. Effect of miR-181a, miR-4301, miR-3960 and miR-4508 on DENV infection of Huh7 cells. Huh7 cells were
transfected with a mimic negative control (NC) and with the indicated miRNA mimics. At 24 hpt, cells were infected at MOIs 1, 5
and 10. The percentage of E-positive cells (grey bars) and infectious virus particle production (black bars) were determined at 24
hpi. The percentages of infection of cells transfected with the NC and infected at MOIs 1, 5 and 10 were 6.57±2.07; 13.9±3.48
and 18.53±2.64 respectively; while the viral titers were 1.2x105±5x104; 1.08x106±2x105 and 7.06 x106±6x104 PFU/ml
respectively. Data is presented as the percentage relative to the NC and shows mean ± SEM from three independent
experiments. Statistical differences were assessed with Student’s t-test.
https://doi.org/10.1371/journal.pntd.0005981.g003
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and the cytoplasm. Furthermore, p150 has been implicated in the editing of viral genomes
which impact on the way viruses interact with their hosts, leading to either enhanced or
reduced infection [15]. First, we evaluated ADAR1 expression in miR-3614-5p transfected
Huh7 cells by western blot analysis. siRNA against ADAR1 was used as a positive control to
decrease protein expression. Non-treated Huh7 cells express both, p110 and a basal level of
p150 (Fig 6). Interestingly, miR-3614-5p, like siADAR1, reduced the expression of the p150
isoform of ADAR1 (Fig 6A) by 51% and 66%, respectively. No significant differences were
found in the protein levels of the p110 isoform at 24 hpt. At 48 hpt, however, siADAR reduced
the levels of the p110 isoform by 70% and further decreased the levels of the p150 isoform by
11% (S5 Fig), which is likely due to the higher expression of the p110 isoform. We next deter-
mined whether miR-3614-5p also decreases ADAR1 expression in DENV-infected cells. Fig
Fig 4. Effect of miR-3614-5p on DENV and WNV infection of Huh7 cells. Huh7 cells were transfected as described in the legend
to Fig 3. (A) Infectious virus particle production at 24 hpi. In cells transfected with NC and infected at MOI 1, 5 and 10 the viral titers
were 1.2x105±5x104; 1.08x106±2x105 and 7.06x106±6x104 PFU/ml respectively. (B) Number of released DENV genome equivalent
particles at 24 hpi. For NC-transfected cells infected at MOIs 1, 5 and 10 the DENV genome equivalent particles per ml were:
2.33x107±1x107; 6.77x107±3x107 and 1.72x108±5x107 respectively. (C) Infectious DENV production following infection at MOI 5 and
harvesting times of 24, 36, 48 hpi. The corresponding viral titers of cells transfected with NC were: 1.08x106±2x105; 2.59x106±1x106
and 2.6x106±1x106 PFU/ml. (D) Infectious WNV production at 12 hpi; in cells transfected with the NC the viral titers were
1.82x105±1x104 and 4.14x105±1.32x105 PFU/ml in upon infection at MOIs 0.5 and 1, respectively. Data is presented as the
percentage relative to the NC and shows mean ± SEM from at least three independent experiments. Statistical differences were
assessed with Student’s t-test.
https://doi.org/10.1371/journal.pntd.0005981.g004
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6B shows that ADAR1 p150 expression is reduced by 36 and 41% in Huh7 cells prior trans-
fected with miR-3614-5p and infected with DENV at MOI 1 and 10, respectively. The moder-
ate but consistent effect of miR-3614-5p on ADAR1 in DENV-infected cells is in line with the
subtle effects seen before, thereby strengthening the importance of miR-3614-5p in regulating
ADAR1 expression.
ADAR1 is induced by DENV in MEFs and favors infection
So far our results showed that 1) miR-3614-5p is upregulated in human MDMs that are
exposed but not infected with DENV, 2) overexpression of miR-3614-5p reduces DENV infec-
tivity and that 3) ADAR1 p150 expression is repressed by miR-3614-5p in mock-infected and
DENV-infected Huh7 cells. In contrast to previously published data [13] we did not observe
an increase in ADAR1 p150 in DENV-infected Huh7 cells when compared to mock-infected
cells (Fig 6B). On the other hand, we did find an MOI-dependent increase of ADAR1 expres-
sion (S6 Fig) in DENV-infected MDMs by microarray analysis [33]. To better understand
these results we next decided to use WT MEFs and ADAR KO MEFs as an alternative, more
stringent, approach to confirm the role of ADAR in DENV infectivity.
In DENV-infected WT MEFs, an MOI-dependent increase in ADAR1 p150 expression was
found. At MOI 1, ADAR p150 increased 5.7-fold and at MOI 5 a 20.9-fold increase was
detected (Fig 7). This suggests that ADAR1 expression is indeed enhanced upon DENV infec-
tion. We do not have an explanation for our results in Huh7 cells yet it might be related to the
high basal levels of ADAR1 in our Huh7 cells as the protein bands are much more intense
when compared to WT MEFs under otherwise similar experimental conditions. Next, we
investigated whether ADAR1 controls DENV replication. To this end, we used ADAR1 and
p53 double KO MEFs as single ADAR1-/- MEFs cannot be cultured long term because of cell
death [39]. S7 Fig confirms that p53-/-ADAR1-/- cells do not express ADAR1. Furthermore,
the expression level of ADAR1 was comparable (not statistically different) in WT and p53-/-
MEFs. DENV infectivity was compared between WT, p53-/- and p53-/-ADAR1-/- MEFs (Fig 8).
The results indicate that both the percentage of infection and the viral titers are significantly
lower in the p53-/-ADAR1-/- MEFs compared to WT and p53-/- MEFs. The percentage of
infected MEFs did not increase beyond 24 hpi, which suggests that MEFs only support one
round of replication (Fig 8, upper panels). Infectious virus particle production plateaus at 30
hpi for control MEFs whereas in the p53-/-ADAR1-/- cells virus particle production continues
till at least 48 hpi (Fig 8, lower panels). At 48 hpi, the number of produced infectious virus par-
ticles by the p53-/-ADAR1-/- MEFs nearly reaches the levels of control cells despite the fact that
the percentage of infected cells at this time point is much lower. Collectively, the data suggests
a dual role for ADAR1. ADAR1 appears to contribute to DENV infectivity at early stages of
infection, whereas it suppresses long-term virus production.
miR-3614-5p overexpression reduces DENV replication in WT MEFs but
not in ADAR KO cells
We next determined whether overexpression of miR-3614-5p impairs DENV infectivity in
WT MEFs and p53-/-ADAR-/- MEFs. The results show that transfection of miR-3614-5p in
Fig 5. Overexpression of miR-3614-5p regulates protein expression in Huh7 cells. Huh7 cells were transfected with a mimic NC and with the
mimic of miR-3614-5p. At 24 hpt changes in protein expression were analyzed by LC/MS. (A) Clustered heat map displaying differentially expressed
proteins between the groups (two independent experiments per group). Underlined proteins were also predicted by bioinformatics tools. (B) Gene set
enrichment analysis of the proteins regulated by the miR-3614-5p. (C) Enriched KEGG pathways upregulated by the miR-3614-5p (PR: positive
regulation, NR: negative regulation).
https://doi.org/10.1371/journal.pntd.0005981.g005
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WT MEFs reduced viral titers by 3.7-fold when compared to cells transfected with the mimic
negative control (Fig 9). On the other hand, transfection of miR-3614-5p into p53-/-ADAR-/-
Fig 6. Overexpression of miR-3614-5p downregulates ADAR1 expression in Huh7 cells. (A) Huh7 cells were transfected
with the mimic of miR-3614-5p or a siRNA against ADAR1 (siADAR). The correspondent negative control (NC) mimic and NC
siRNA were also used. At 24 hpt, total protein was extracted and ADAR1 expression was detected by western blot. (B) Huh7
cells were transfected with the mimic of miR-3614-5p and NC. At 24 hpt, cells were infected with DENV at MOI 1 and 10. At 24
hpi, total protein was extracted and ADAR1 expression was detected by western blot. (A, B) The expression of ADAR1 was
normalized to that of GAPDH and it is expressed as the percentage of the cells transfected with the correspondent NC. Data
shows mean ± SEM from three independent experiments. Differences were assessed with Student’s t-test.
https://doi.org/10.1371/journal.pntd.0005981.g006
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cells did not have an effect on infectious DENV production. This data confirms that miR-
3614-5 reduces DENV infection through regulation of ADAR1.
Discussion
We anticipated that DENV would induce significant changes in the miRNAome of infected
cells. However, our results show that only very few miRNAs are regulated in DENV-chal-
lenged MDMs. Furthermore, the miRNAs that are specifically upregulated in DENV-infected
cells do not impact infectious virus particle production. On the contrary, miR-3614-5p, which
was upregulated in DENV-negative MDMs, had a moderate but significant antiviral effect.
MiR-3614-5p was observed to downregulate the expression of the IFN-induced p150 isoform
of ADAR1. Furthermore, cells that do not express ADAR1 are less permissive to DENV infec-
tion. Taken together, through this screen, we identified a novel miRNA with antiviral proper-
ties towards two clinically relevant flaviviruses.
Unique to our approach is that we used human primary macrophages and differentiated
between truly DENV-infected cells and cells that despite being exposed to virus were not
infected. This approach revealed that only 5 miRNAs are differentially expressed. The overall
low number of miRNAs that are regulated upon DENV infection is in line with other studies
in cell lines. For example, Wu et. al described that infection of human endothelial cells (EA.
hy926) with DENV induced upregulation of 8 miRNAs and downregulation of 4 miRNAs
[40]. Similarly, Escalera-Cueto and colleagues reported that 9 miRNAs are regulated upon
Fig 7. DENV infection induces ADAR1 expression in MEFs. MEFs were infected with DENV at the
indicated MOIs. The methodology is as described in the legend to Fig 6. The expression of ADAR1 was
normalized to that of GAPDH and it is expressed as the percentage of the mock-infected cells. Data shows
mean ± SEM from three independent experiments.
https://doi.org/10.1371/journal.pntd.0005981.g007
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DENV infection of Huh7 cells [41]. None of the previously reported miRNAs were found in
our study, revealing the strong cellular-context dependency of miRNA regulation in response
to DENV infection. The low number of miRNAs regulated in DENV-infected cells and the
lack of overlap among different cell types strongly suggest that cellular miRNAs do not play a
key role during DENV replication.
None of the miRNAs upregulated in the DENV-plus population of MDMs had an impact
on DENV infectivity in Huh7 cells. It therefore appears that none of these miRNAs have a uni-
versally beneficial effect on DENV replication. We, however, cannot rule out potential proviral
functions of these miRNAs in MDMs. Alternatively, their increased expression might be a
response to either cellular stress or immune activation induced by the infection [42,43]. For
example, an increased expression of miR-4508 and miR-4301 has been observed in several
cancer types [44–47] and it was previously reported that miR-3960 can be used as a marker for
type 2 diabetes [48]. The observation that these miRNAs can be induced by diverse stimuli,
points towards a general mechanism of activation, likely mediated by cellular stress and/or
immune responses.
Fig 8. ADAR KO MEFs are less permissive to DENV than wild-type MEFs. Wild-type (WT) MEFs, p53 KO MEFs (p53-/-) and
p53/ADAR double KO MEFs (ADAR-/-) were infected with DENV at MOIs 1 and 5. At the indicated time points, the percentage of
infection (upper panels) was determined by flow cytometry and the infectious virus particle production (lower panels) by plaque
assay. Data shows mean ± SEM from three independent experiments.
https://doi.org/10.1371/journal.pntd.0005981.g008
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MiR-3614-5p, on the other hand, was found upregulated in DENV-neg MDMs and its
overexpression had a moderate but significant negative effect on DENV and WNV infectivity
in Huh7 cells. MiR-3614 is not regulated in cells treated with UV-iDENV, suggesting that the
expression level of miR-3614 is increased as a consequence of abortive infection or is triggered
by soluble factors secreted by infected cells. Although the contribution of miRNAs in regulat-
ing replication of mammalian-infecting viruses is highly debated [49,50], we found a consis-
tent reduction of DENV and WNV infectivity. Furthermore, antiviral activity of many other
miRNAs in other viral systems have been reported [21,22]. The observed effect of miRNAs on
virus replication is generally subtle, though this is expected as miRNAs are fine-tuners of gene
expression, reducing protein levels of their targets by on average 2-fold [24,41,51–55]. In addi-
tion, the use of redundant host factors by mammalian-infecting viruses could add to the lim-
ited effect of individual miRNAs on virus production.
To elucidate the mode of action for miR-3614-5p, we performed proteomic analysis of
miR-3614-5p-overexpressing cells. The results revealed that 9 proteins are downregulated and
20 proteins are upregulated in response to miR-3614-5p. Some of the identified proteins have
been implicated in the replication cycle of mammalian viruses. For example, protein S100-A9
(S100A9) and α-actinin-4 (ACTN4) were described to enhance influenza A virus infection,
and dynein light chain 1 (DYNLL1) has been implicated in the transcription of human immu-
nodeficiency virus [56–58]. Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
was found to participate in Japanese encephalitis virus replication [59] and was described to
bind to the 3’UTR of DENV RNA [60]. A clear role for HNRNPA2B1 during DENV infection
was, however, not determined [60,61]. Additionally, ADAR1 has been reported as a proviral
factor for multiple viruses [14]. We examined the role of miR3614-5p in regulating ADAR1
expression and showed that miR-3614-5p reduces ADAR1 p150 protein levels in mock-
infected and DENV-infected cells. Two distinct methodologies were used in this analysis and
therefore it is likely that miR-3614-5p regulates ADAR1 expression. To confirm ADAR1 as a
direct target of miR-3614-5p other experiments such as the use of reporter assays might be
Fig 9. miR-3614-5p impairs DENV production in WT MEFs but not in ADAR KO cells. WT and
p53-/-ADAR1-/- cells were transfected with the mimic of miR-3614-5p or the correspondent negative control
(NC). At 24 hpt, cells were infected with DENV at MOI 5. At 24 hpi, cell supernatants were titrated by plaque
assay. Data shows mean ± SEM from three independent experiments. Differences were assessed with
Student’s t-test.
https://doi.org/10.1371/journal.pntd.0005981.g009
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required. In addition, future research should dissect whether miR-3614-5p- also regulates the
expression of the other proteins identified by LC/MS.
De Chassey and colleagues reported that DENV infection of Huh7 cells increases ADAR1
expression. Furthermore, silencing of ADAR1 through siRNAs was found to decrease DENV
replication [13]. Although in our system, DENV did not alter the expression of ADAR1 in
Huh7 cells, we did observe an increase in ADAR1 levels in MDMs and WT MEFs. We specu-
late that the discrepancies between previously published data [13] and our results in Huh7
cells, might relate to the basal levels of ADAR1. The higher basal levels of ADAR1 in our Huh7
cells when compared to MEFs is in line with the stronger effect of miR-3614-5p on DENV
infectivity observed in MEFs (3.7-fold decrease) when compared to Huh7 cells (2.8-fold
decrease). In WT MEFs, DENV infection specifically upregulated the IFN-inducible p150 iso-
form, suggesting that virus-induced IFN might play an active role in this phenomenon. Fur-
thermore, ADAR1 KO MEFs were less susceptible to DENV infection and initially produced
lower numbers of progeny infectious virus particles. At late time points, however, virus particle
production per infected cell is much higher in the ADAR1 KO MEFs. Collectively, this
strongly suggests that ADAR1 acts as a proviral factor early in replication whereas at late time
points it represses DENV replication. DENV infection was shown to increase the overall
ADAR1 editing activity [13]. Thus, it is likely that viral RNA is subjected to A-to-I modifica-
tions which have been associated with the suppression of innate immune responses, thereby
allowing more efficient replication early in infection [39,62,63]. However, the exact mecha-
nism by which ADAR1 promotes and later limits DENV infectivity remains to be elucidated.
We show that miR-3614-5p has antiviral activity towards flaviviruses and regulates ADAR1
expression, yet future studies should unravel whether there is a direct causal link between
these findings. Furthermore, it remains to be elucidated whether MDMs are more refractory
to infection due to upregulation of miR-3614-5p. Dissecting the molecular actions of miR-
3614-5p will deepen our understanding of the replication cycle of flaviviruses and how the
expression of miRNAs is regulated in primary human/relevant cell types.
Supporting information
S1 Fig. MDMs are susceptible to the infection by a recombinant GFP-DENV. MDMs from
three different donors (D29, D30, D28) were infected at MOI 10 with a recombinant
GFP-DENV. At 24 hours post-infection, the percentage of GFP-positive cells was determined
by flow cytometry.
(TIF)
S2 Fig. Hierarchical unsupervised Pearson correlation of miRNAs detected in MDMs chal-
lenged with DENV. MDMs from three different blood donors (D28, D29 and D23) treated as
follow: 1) mock-infected, 2) treated with UVi-DENV, 3) challenged with GFP-DENV (DENV-
challenge), 4) challenged with GFP-DENV and sorted for GFP positive cells (DENV-plus), 5)
challenged with GFP-DENV and sorted for GFP negative cells (DENV-neg).
(TIF)
S3 Fig. FACs sorting does not influence the expression of miRNAs in MDMs. (A) Hierar-
chical unsupervised Pearson correlation of miRNAs detected in MDMs mock-infected non-
sorted (NS) and passed through the FACs sorting. (B) Comparison average number of reads
per million (RPM) from mock-infected NS and mock-infected sorted cells. No differences
were found between the groups when a moderated T test was applied.
(TIF)
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S4 Fig. Effect of mimics transfection on DENV infectivity and cell viability. Cells were
transfected at a final concentration of 10nM of the indicated miRNA mimic or not transfected
(NT). At 24 hpt, MDMs (A) and Huh7 (B) were infected at MOIs 1, 5 and 10. At 24 hpi, the
percentage of E-positive cells was determined by flow cytometry. Data is presented as the per-
centage relative to the NT cells and shows mean ± SEM from three different blood donors (A)
and at least three independent experiments (B). Differences were assessed with Student’s t-test.
(C) At 24 hpt, viability of Huh7 cells was determined. Data shows mean ± SEM from three
independent experiments.
(TIF)
S5 Fig. Overexpression of miRNA-3614-5p downregulates ADAR1 expression in Huh7
cells. Huh7 cells were transfected with the mimic of miRNA-3614-5p or a siRNA against
ADAR1 (siADAR). The correspondent negative control (NC) mimic and NC siRNA were also
used. At 48 hpt, total protein was extracted and ADAR1 expression was detected by western
blot. The expression of ADAR1 was normalized to that of GAPDH and it is expressed as the
percentage of the cells transfected with the correspondent NC. Data shows mean ± SEM from
three independent experiments. Differences were assessed with Student’s t-test.
(TIF)
S6 Fig. DENV infection induces ADAR1 expression in human MDMs. MDMs were infected
with DENV at the indicated MOIs and at 24 hpi total RNA was extracted. Gene expression
was investigated by microarray [33]. Probe values were normalized against the total signal
intensity of the sample and subsequently, the fold change of the probes were expressed relative
to the mock condition of the same donor taking into account the house keeping genes (HKGs)
GAPDH, β-actin, β-glucuronidase, Hypoxanthine-guanine phosphoribosyltransferase and
heat shock protein 90β1. Data shows mean ± SD from four different blood donors.
(TIF)
S7 Fig. ADAR1 expression in wild-type and KO MEFs. Representative blot of ADAR1
expression in cultured wild-type MEFs (WT), p53 KO MEFs (p53-/-) and p53/ADAR double
KO MEFs (p53-/-ADAR-/-). The expression of ADAR1 was normalized to that of GAPDH and
it is expressed as the percentage of the WT cells. Data shows mean ± SEM from three indepen-
dent experiments. ND, no determined.
(TIF)
S1 Table. List of miR-3614-5p targets predicted by miRWalk.
(XLSX)
S2 Table. List of proteins identified by mass spectrometry.
(XLSX)
S3 Table. KEEGG pathways altered by the overexpression of miR-3614-5p.
(XLSX)
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